rechARge: A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - Sep 9, 2026 - P3 | N=960 | Active, not recruiting | Sponsor: Celgene | Recruiting ➔ Active, not recruiting
Enrollment closed • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
|